Perceptive Advisors LLC Biogen Inc. Call Options Transaction History

Perceptive Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $194 Million - $310 Million	-748,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$242.95 - $284.63 $182 Million - $213 Million	748,000 New	748,000 $209 Million
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $23.6 Million - $35.6 Million	-100,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$264.77 - $305.71 $26.5 Million - $30.6 Million	100,000 New	100,000 $28.4 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $43.5 Million - $48.8 Million	-200,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $43.9 Million - $48.3 Million	-200,000 Reduced 50.0%	200,000 $65,000
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $86.7 Million - $136 Million	400,000 New	400,000 $620,000
Q2 2018 Aug 14, 2018	SELL	$257.52 - $306.91 $12.9 Million - $15.3 Million	-50,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $13 Million - $18.4 Million	50,000 New	50,000 $11,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.